Allspring Global Investments Holdings LLC Has $8.71 Million Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Allspring Global Investments Holdings LLC increased its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 13.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 417,332 shares of the biopharmaceutical company’s stock after purchasing an additional 50,888 shares during the period. Allspring Global Investments Holdings LLC owned approximately 0.35% of Catalyst Pharmaceuticals worth $8,710,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in CPRX. Pacer Advisors Inc. raised its position in Catalyst Pharmaceuticals by 5.4% in the fourth quarter. Pacer Advisors Inc. now owns 2,955,508 shares of the biopharmaceutical company’s stock worth $61,681,000 after acquiring an additional 151,495 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in shares of Catalyst Pharmaceuticals by 4.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,167,743 shares of the biopharmaceutical company’s stock worth $23,215,000 after purchasing an additional 50,804 shares during the period. abrdn plc purchased a new position in Catalyst Pharmaceuticals in the fourth quarter valued at approximately $10,115,000. JPMorgan Chase & Co. lifted its stake in Catalyst Pharmaceuticals by 9.1% in the third quarter. JPMorgan Chase & Co. now owns 408,261 shares of the biopharmaceutical company’s stock valued at $8,116,000 after purchasing an additional 33,888 shares during the last quarter. Finally, Jane Street Group LLC grew its holdings in Catalyst Pharmaceuticals by 245.4% during the third quarter. Jane Street Group LLC now owns 401,908 shares of the biopharmaceutical company’s stock valued at $7,990,000 after purchasing an additional 285,564 shares during the period. 79.22% of the stock is owned by institutional investors.

Analyst Ratings Changes

CPRX has been the topic of several research reports. Baird R W upgraded Catalyst Pharmaceuticals to a “strong-buy” rating in a research note on Monday, February 3rd. Stephens initiated coverage on shares of Catalyst Pharmaceuticals in a report on Monday, November 18th. They set an “overweight” rating and a $35.00 price objective on the stock. Robert W. Baird began coverage on shares of Catalyst Pharmaceuticals in a research report on Tuesday, February 4th. They issued an “outperform” rating and a $28.00 price target on the stock. Bank of America reiterated a “buy” rating and set a $30.00 target price on shares of Catalyst Pharmaceuticals in a research report on Thursday, January 9th. Finally, HC Wainwright increased their price objective on Catalyst Pharmaceuticals from $30.00 to $35.00 and gave the company a “buy” rating in a research report on Friday, January 10th. Nine equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $32.25.

Insiders Place Their Bets

In other Catalyst Pharmaceuticals news, insider Steve Miller sold 50,000 shares of the stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $21.93, for a total value of $1,096,500.00. Following the completion of the transaction, the insider now owns 686,996 shares in the company, valued at approximately $15,065,822.28. This represents a 6.78 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Gary Ingenito sold 12,000 shares of the company’s stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $22.72, for a total transaction of $272,640.00. Following the completion of the sale, the insider now directly owns 51,391 shares in the company, valued at $1,167,603.52. This represents a 18.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 79,500 shares of company stock worth $1,754,140 over the last three months. Company insiders own 11.00% of the company’s stock.

Catalyst Pharmaceuticals Price Performance

Shares of CPRX stock opened at $22.94 on Wednesday. The business has a 50-day moving average of $22.21 and a 200 day moving average of $21.19. The stock has a market capitalization of $2.74 billion, a PE ratio of 19.44, a P/E/G ratio of 3.46 and a beta of 0.80. Catalyst Pharmaceuticals, Inc. has a 1-year low of $13.49 and a 1-year high of $24.64.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.